Palmitoylethanolamide is an endogenous fatty acid amide, and exerts a great variety of biological functions related to chronic pain and inflammation. Research has shown it to be anti-nociceptive, neuroprotective and have anticonvulsant properties. Research also shows it reduces the raised intraocular pressure of glaucoma. From a clinical perspective the most important and promising indications for PEA are linked to neuropathic and chronic pain states, such as diabetic neuropathic pain, sciatic pain, CRPS, pelvic pain and entrapment neuropathic pain states and atopic ezcema.
Our own clinical studies have found this compound to be effective in the management of certain specific pain conditions and migraine headaches.